~~<i id='A105398A41'><strike id='A105398A41'><tt id='A105398A41'><pre id='A105398A41'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：knowledge 2025-09-06 02:13:49 - browse：5346

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Illumina slashes 2023 revenue projections yet again

Wikipedia

knowledge

hotspot

leisure time

hotspot

AdobeEliLillysaidTuesdaythatitwillpay$200milliontogene-editingfirmBeamTherapeuticsforBeam’sstakeinVe

WSS

Timeline: How the deadly wildfires took over Maui day by day

Paying for Covid pills will soon shift to insurers

After Optum profits sink, UnitedHealth makes changes

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Bird flu researchers hone in on Finland’s mink farms

Montana youths win climate lawsuit against state for promoting fossil fuels

explore

hotspot

Wikipedia

Supreme Court strikes down use of affirmative action

Idaho college killings prosecutors challenge defense's grand jury claims

State Dept. review finds Biden bears some blame for Afghanistan failures

Maker of FluMist seeks to allow at

In age of alternative facts, a scholarly course on calling out crap

Eli Lilly to pay $200M for Beam’s stake in gene

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Senate panel to vote on hospitals, PBMs, prisoner care

Trump demands the U.S. pay no more for drugs than other countries … again

After Optum profits sink, UnitedHealth makes changes

knowledge

Dozens dead from Maui wildfires: What we know about the victims

Surge in Apellis stock fueled by confidence in safety of its eye drug

Medtronic CEO on promising devices for diabetes, hypertension

YouTube cracks down on misinformation on cancer treatment

After Optum profits sink, UnitedHealth makes changes

Novo Nordisk touts Wegovy study, but still struggling with supply

knowledge

hotspot

leisure time

hotspot